Glaxo: Avandia critic should pay for stock drop

A researcher and early critic of Avandia told Congress yesterday that a GlaxoSmithKline executive threatened him with dire financial consequences when he raised concerns about the drug. Dr. John Buse, who testified before a House panel yesterday, told investigators that Glaxo executive Dr. Tadataka Yamada suggested that he should be responsible for the $4 billion drop in stock value Glaxo suffered after Avandia safety concerns came to light. In light of similar findings by Dr. Steven Nissen, a Cleveland Clinic cardiologist, the FDA is now asking Glaxo--as well as Actos maker Takeda--to put "black box" warnings on the popular drugs. Nissen's findings suggest that Avandia, Glaxo's drug, increases a patient's odds of suffering a heart attack.

To learn more about Buse's concerns:
- read this article from The Boston Globe

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.